Table 23 Findings of the replicated studies compared to our results
| Â | Finding | Rep. |
|---|---|---|
| Â | Main findings | Â |
1 | The absolute number of patients initiating OAC has increased among patients aged <65, 65 to 74, and ≥85 years | yes |
2 | The utilization of VKAs has decreased since the introduction of NOACs | yes |
3 | From 2014 [to 2015] the utilization of dabigatran has decreased, especially among patients aged ≥85 years | yes |
4 | Apixaban has increased significantly and was the most used NOAC drug among patients aged ≥85 years | (yes) |
| Â | Other results | Â |
5 | For patients aged 75 to 84 years, number of patients initiating OAC treatment stayed approximately the same | no |
6 | The utilization of dabigatran increased within a couple of months since its introduction to the market | yes |
7 | A fairly constant level of dabigatran utilization was seen from December 2011 of approximately 40% | no |
8 | Rivaroxaban has steadily increased usage and at study end 29% | yes |